Home > Insider Trading > Biontech Se

Biontech Se (BNTX)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

1 - 10
Next >>

Truist Lifts BioNTech (BNTX) Price Target After New Partnership

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and co-commercialization of BioNTech SE’s (NASDAQ:BNTX) investigational bispecific antibody...

Keep Reading →

June 3rd, 2025 - News

Why BioNTech SE (BNTX) Skyrocketed On Monday

We recently published a list of These 10 Stocks Blew Past Expectations.

Keep Reading →

June 3rd, 2025 - News

Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market.

Keep Reading →

June 2nd, 2025 - News

Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal

On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation oncology therapies...

Keep Reading →

June 2nd, 2025 - News

BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion

German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing...

Keep Reading →

May 21st, 2025 - News